Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients
The prognosis of patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) remains uncertain and no standardized follow-up programs have been established. To recommend a standardized follow-up program of patients with AFX and PDS based on nationwide long-term estimates of local...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology 2023-12, Vol.89 (6), p.1177-1184 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1184 |
|---|---|
| container_issue | 6 |
| container_start_page | 1177 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 89 |
| creator | Ørholt, Mathias Abebe, Kiya Rasmussen, Louise E. Aaberg, Frederik L. Lindskov, Lærke J. Schmidt, Grethe Wagenblast, Anne Lene Petersen, Michael M. Loya, Anand C. Daugaard, Søren Herly, Mikkel Jensen, David Hebbelstrup Vester-Glowinski, Peter |
| description | The prognosis of patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) remains uncertain and no standardized follow-up programs have been established.
To recommend a standardized follow-up program of patients with AFX and PDS based on nationwide long-term estimates of local recurrence and metastasis.
All patients with AFX and PDS in Denmark between 2002 and 2022 were included. Danish National Registries were used to estimate the risks of local recurrence and metastasis for AFX and PDS.
The 5-year risk of local recurrence was 10% for AFX and 17% for PDS. The 5-year risk of metastasis was 0.8% for AFX and 16% for PDS. PDS metastasized within 3 years in >90% of the patients with the lungs as the primary metastasis site (50%). Invasion beyond the subcutis, perineural/intravascular infiltration, and increasing age significantly increased the risk of PDS relapse.
Risk of misclassification and lack of detailed surgical information.
The follow-up of patients with AFX can be limited to clinical visits for 4 years. Patients with PDS should be followed with clinical visits and PET/CT twice a year for the first 3 years and once a year for a minimum of 1 year. |
| doi_str_mv | 10.1016/j.jaad.2023.08.050 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2858406682</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962223026282</els_id><sourcerecordid>2858406682</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-9fa8a2dfe136336eebe47c489cd8ba8f4eda1c47fe9a72ae34022371709c53333</originalsourceid><addsrcrecordid>eNp9kM2KFDEURoMo2I6-gKss3VR5k1RXUuJmGPwZaJiNrsPt5BadpqpSJml1nsJXNjXt2hAI4fvOhXsYeyugFSD69-f2jOhbCVK1YFrYwzO2EzDoptdGP2c7EAM0Qy_lS_Yq5zMADJ3SO_bntjyuweHEx3BM8Tcu5RRn5Lh4vk4U55jWU3DcU5prKWNyNf7AD3FjErlLSrQ4egJmKpjrDZmHhSNfsIS4_Aqe-BrXy_T0bY6YyXMXTzEVHkcuhDB8rRktJb9mL0acMr35996w758_fbv72hwevtzf3R4ap7QuzTCiQelHEqpXqic6UqddZwbnzRHN2JFH4To90oBaIqkOpFRaaBjcXtVzw95d564p_rhQLnYO2dE04ULxkq00e9NB3xtZq_JadSnmnGi0awozpkcrwG727dlu9u1m34Kx1X6FPl4hqkv8DJRsdmET5UOVVqyP4X_4X6SokNg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2858406682</pqid></control><display><type>article</type><title>Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Ørholt, Mathias ; Abebe, Kiya ; Rasmussen, Louise E. ; Aaberg, Frederik L. ; Lindskov, Lærke J. ; Schmidt, Grethe ; Wagenblast, Anne Lene ; Petersen, Michael M. ; Loya, Anand C. ; Daugaard, Søren ; Herly, Mikkel ; Jensen, David Hebbelstrup ; Vester-Glowinski, Peter</creator><creatorcontrib>Ørholt, Mathias ; Abebe, Kiya ; Rasmussen, Louise E. ; Aaberg, Frederik L. ; Lindskov, Lærke J. ; Schmidt, Grethe ; Wagenblast, Anne Lene ; Petersen, Michael M. ; Loya, Anand C. ; Daugaard, Søren ; Herly, Mikkel ; Jensen, David Hebbelstrup ; Vester-Glowinski, Peter</creatorcontrib><description>The prognosis of patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) remains uncertain and no standardized follow-up programs have been established.
To recommend a standardized follow-up program of patients with AFX and PDS based on nationwide long-term estimates of local recurrence and metastasis.
All patients with AFX and PDS in Denmark between 2002 and 2022 were included. Danish National Registries were used to estimate the risks of local recurrence and metastasis for AFX and PDS.
The 5-year risk of local recurrence was 10% for AFX and 17% for PDS. The 5-year risk of metastasis was 0.8% for AFX and 16% for PDS. PDS metastasized within 3 years in >90% of the patients with the lungs as the primary metastasis site (50%). Invasion beyond the subcutis, perineural/intravascular infiltration, and increasing age significantly increased the risk of PDS relapse.
Risk of misclassification and lack of detailed surgical information.
The follow-up of patients with AFX can be limited to clinical visits for 4 years. Patients with PDS should be followed with clinical visits and PET/CT twice a year for the first 3 years and once a year for a minimum of 1 year.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2023.08.050</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>atypical fibroxanthoma ; local recurrence ; metastasis ; pleomorphic dermal sarcoma ; prognosis ; relapse ; risk factors</subject><ispartof>Journal of the American Academy of Dermatology, 2023-12, Vol.89 (6), p.1177-1184</ispartof><rights>2023 American Academy of Dermatology, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-9fa8a2dfe136336eebe47c489cd8ba8f4eda1c47fe9a72ae34022371709c53333</citedby><cites>FETCH-LOGICAL-c377t-9fa8a2dfe136336eebe47c489cd8ba8f4eda1c47fe9a72ae34022371709c53333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0190962223026282$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><creatorcontrib>Ørholt, Mathias</creatorcontrib><creatorcontrib>Abebe, Kiya</creatorcontrib><creatorcontrib>Rasmussen, Louise E.</creatorcontrib><creatorcontrib>Aaberg, Frederik L.</creatorcontrib><creatorcontrib>Lindskov, Lærke J.</creatorcontrib><creatorcontrib>Schmidt, Grethe</creatorcontrib><creatorcontrib>Wagenblast, Anne Lene</creatorcontrib><creatorcontrib>Petersen, Michael M.</creatorcontrib><creatorcontrib>Loya, Anand C.</creatorcontrib><creatorcontrib>Daugaard, Søren</creatorcontrib><creatorcontrib>Herly, Mikkel</creatorcontrib><creatorcontrib>Jensen, David Hebbelstrup</creatorcontrib><creatorcontrib>Vester-Glowinski, Peter</creatorcontrib><title>Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients</title><title>Journal of the American Academy of Dermatology</title><description>The prognosis of patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) remains uncertain and no standardized follow-up programs have been established.
To recommend a standardized follow-up program of patients with AFX and PDS based on nationwide long-term estimates of local recurrence and metastasis.
All patients with AFX and PDS in Denmark between 2002 and 2022 were included. Danish National Registries were used to estimate the risks of local recurrence and metastasis for AFX and PDS.
The 5-year risk of local recurrence was 10% for AFX and 17% for PDS. The 5-year risk of metastasis was 0.8% for AFX and 16% for PDS. PDS metastasized within 3 years in >90% of the patients with the lungs as the primary metastasis site (50%). Invasion beyond the subcutis, perineural/intravascular infiltration, and increasing age significantly increased the risk of PDS relapse.
Risk of misclassification and lack of detailed surgical information.
The follow-up of patients with AFX can be limited to clinical visits for 4 years. Patients with PDS should be followed with clinical visits and PET/CT twice a year for the first 3 years and once a year for a minimum of 1 year.</description><subject>atypical fibroxanthoma</subject><subject>local recurrence</subject><subject>metastasis</subject><subject>pleomorphic dermal sarcoma</subject><subject>prognosis</subject><subject>relapse</subject><subject>risk factors</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kM2KFDEURoMo2I6-gKss3VR5k1RXUuJmGPwZaJiNrsPt5BadpqpSJml1nsJXNjXt2hAI4fvOhXsYeyugFSD69-f2jOhbCVK1YFrYwzO2EzDoptdGP2c7EAM0Qy_lS_Yq5zMADJ3SO_bntjyuweHEx3BM8Tcu5RRn5Lh4vk4U55jWU3DcU5prKWNyNf7AD3FjErlLSrQ4egJmKpjrDZmHhSNfsIS4_Aqe-BrXy_T0bY6YyXMXTzEVHkcuhDB8rRktJb9mL0acMr35996w758_fbv72hwevtzf3R4ap7QuzTCiQelHEqpXqic6UqddZwbnzRHN2JFH4To90oBaIqkOpFRaaBjcXtVzw95d564p_rhQLnYO2dE04ULxkq00e9NB3xtZq_JadSnmnGi0awozpkcrwG727dlu9u1m34Kx1X6FPl4hqkv8DJRsdmET5UOVVqyP4X_4X6SokNg</recordid><startdate>202312</startdate><enddate>202312</enddate><creator>Ørholt, Mathias</creator><creator>Abebe, Kiya</creator><creator>Rasmussen, Louise E.</creator><creator>Aaberg, Frederik L.</creator><creator>Lindskov, Lærke J.</creator><creator>Schmidt, Grethe</creator><creator>Wagenblast, Anne Lene</creator><creator>Petersen, Michael M.</creator><creator>Loya, Anand C.</creator><creator>Daugaard, Søren</creator><creator>Herly, Mikkel</creator><creator>Jensen, David Hebbelstrup</creator><creator>Vester-Glowinski, Peter</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202312</creationdate><title>Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients</title><author>Ørholt, Mathias ; Abebe, Kiya ; Rasmussen, Louise E. ; Aaberg, Frederik L. ; Lindskov, Lærke J. ; Schmidt, Grethe ; Wagenblast, Anne Lene ; Petersen, Michael M. ; Loya, Anand C. ; Daugaard, Søren ; Herly, Mikkel ; Jensen, David Hebbelstrup ; Vester-Glowinski, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-9fa8a2dfe136336eebe47c489cd8ba8f4eda1c47fe9a72ae34022371709c53333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>atypical fibroxanthoma</topic><topic>local recurrence</topic><topic>metastasis</topic><topic>pleomorphic dermal sarcoma</topic><topic>prognosis</topic><topic>relapse</topic><topic>risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ørholt, Mathias</creatorcontrib><creatorcontrib>Abebe, Kiya</creatorcontrib><creatorcontrib>Rasmussen, Louise E.</creatorcontrib><creatorcontrib>Aaberg, Frederik L.</creatorcontrib><creatorcontrib>Lindskov, Lærke J.</creatorcontrib><creatorcontrib>Schmidt, Grethe</creatorcontrib><creatorcontrib>Wagenblast, Anne Lene</creatorcontrib><creatorcontrib>Petersen, Michael M.</creatorcontrib><creatorcontrib>Loya, Anand C.</creatorcontrib><creatorcontrib>Daugaard, Søren</creatorcontrib><creatorcontrib>Herly, Mikkel</creatorcontrib><creatorcontrib>Jensen, David Hebbelstrup</creatorcontrib><creatorcontrib>Vester-Glowinski, Peter</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ørholt, Mathias</au><au>Abebe, Kiya</au><au>Rasmussen, Louise E.</au><au>Aaberg, Frederik L.</au><au>Lindskov, Lærke J.</au><au>Schmidt, Grethe</au><au>Wagenblast, Anne Lene</au><au>Petersen, Michael M.</au><au>Loya, Anand C.</au><au>Daugaard, Søren</au><au>Herly, Mikkel</au><au>Jensen, David Hebbelstrup</au><au>Vester-Glowinski, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><date>2023-12</date><risdate>2023</risdate><volume>89</volume><issue>6</issue><spage>1177</spage><epage>1184</epage><pages>1177-1184</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><abstract>The prognosis of patients with atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS) remains uncertain and no standardized follow-up programs have been established.
To recommend a standardized follow-up program of patients with AFX and PDS based on nationwide long-term estimates of local recurrence and metastasis.
All patients with AFX and PDS in Denmark between 2002 and 2022 were included. Danish National Registries were used to estimate the risks of local recurrence and metastasis for AFX and PDS.
The 5-year risk of local recurrence was 10% for AFX and 17% for PDS. The 5-year risk of metastasis was 0.8% for AFX and 16% for PDS. PDS metastasized within 3 years in >90% of the patients with the lungs as the primary metastasis site (50%). Invasion beyond the subcutis, perineural/intravascular infiltration, and increasing age significantly increased the risk of PDS relapse.
Risk of misclassification and lack of detailed surgical information.
The follow-up of patients with AFX can be limited to clinical visits for 4 years. Patients with PDS should be followed with clinical visits and PET/CT twice a year for the first 3 years and once a year for a minimum of 1 year.</abstract><pub>Elsevier Inc</pub><doi>10.1016/j.jaad.2023.08.050</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 2023-12, Vol.89 (6), p.1177-1184 |
| issn | 0190-9622 1097-6787 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2858406682 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | atypical fibroxanthoma local recurrence metastasis pleomorphic dermal sarcoma prognosis relapse risk factors |
| title | Atypical fibroxanthoma and pleomorphic dermal sarcoma: Local recurrence and metastasis in a nationwide population-based cohort of 1118 patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T02%3A01%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atypical%20fibroxanthoma%20and%20pleomorphic%20dermal%20sarcoma:%20Local%20recurrence%20and%20metastasis%20in%20a%20nationwide%20population-based%20cohort%20of%201118%20patients&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=%C3%98rholt,%20Mathias&rft.date=2023-12&rft.volume=89&rft.issue=6&rft.spage=1177&rft.epage=1184&rft.pages=1177-1184&rft.issn=0190-9622&rft.eissn=1097-6787&rft_id=info:doi/10.1016/j.jaad.2023.08.050&rft_dat=%3Cproquest_cross%3E2858406682%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2858406682&rft_id=info:pmid/&rft_els_id=S0190962223026282&rfr_iscdi=true |